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Improved surgical techniques and superior post-
transplant carehave increasedgraft survival after solid
organ transplantation, and complications of lifelong
immunosuppression are increasingly prevalent in
clinical practice. The excess relative risk ofmelanoma
attributable to transplantation is between 2 and 12
times that of the general population,1 and given the
high tumor burden, this has important implications
for the surveillance and management of organ trans-
plant recipients (OTRs). Several risk factors for
melanoma are known, including immunosuppres-
sion, the presence of atypical nevi, light skin photo-
type, ultraviolet light exposure, and a family or
personal history of skin cancer.1,2 Here we report a
case of cutaneous melanoma arising posttransplant,
highlighting the substantialmorbidity andmortality of
this disease in OTR. In view of the increased risk of
melanoma and high potential for metastasis, derma-
tologists should monitor OTRs closely and institute
multidisciplinary care without delay.CASE
A 66-year-old white woman with Fitzpatrick skin
type II received a heart transplant in 2001 for familial
hypertrophic cardiomyopathy and was maintained
on cyclosporine. She presented to the dermatology
department in 2005 for the evaluation of a rapidly
growing pigmented lesion on the umbilicus. A
biopsied found this lesion was a primary malignant
melanoma of 17.5 mm Breslow thickness. Wide localthe Departments of Dermatologya and Medicine,b University
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ail: arrons@derm.ucsf.edu.excision was performed, and sentinel lymph node
biopsy found 1 of 1 positive node in the left side of the
groin and 0 of 1 positive nodes in the right side of the
groin. In 2008, surveillance positron emission tomog-
raphy (PET)/computed tomography (CT) detected
left groin node recurrence, and a subsequent radical
left inguinal dissection found nodal positivity in 18 of
21 nodes. At that time, the patient underwent defin-
itive adjuvant radiation treatment to the left groin.
In 2011, a surveillance PET/CT found multifocal
retroperitoneal lymphadenopathy, and a diagnosis
of metastatic melanoma was confirmed by CT-
guided biopsy. A BRAF V600E mutation was de-
tected, and the patient was enrolled in a phase 3
clinical trial evaluating combined dabrafenib and
trametinib therapy (selective BRAF and mitogen-
activated protein kinases inhibitors, respectively).
She tolerated the regimenwell, showing no evidence
of disease recurrence for 15 months. Unfortunately, a
single metastasis was found in the right side of the
skull in 2013, which was managed with stereotactic
radiotherapy (15000 Gy). Because of tumor progres-
sion, the patient was withdrawn from the study and
unfortunately died from complications of metastatic
disease later in the year.JAAD Case Reports 2015;1:S23-5.
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Three distinct clinical entities are of interest in
relation to melanoma in the OTR: donor-derived
melanoma, melanoma preceding organ transplanta-
tion, and de novo melanoma arising after transplant.
In this report, we focus on de novo posttransplant
melanoma, the scenario most frequently encoun-
tered in clinical practice. Melanoma is an immune
responsive tumor, and the regression of benign and
malignant melanocytic lesions in response to im-
mune mechanisms is well documented.1,2 Iatrogenic
immunosuppression, therefore, is expected to
worsen melanoma outcomes after transplantation,
although to date no population-based study with
adequate power has addressed this issue in OTRs.
Small, retrospective studies have found that Breslow
thickness is inversely correlated with melanoma
survival in this population.1,3-5 In a case series of
100 transplant patients, Matin et al6 found that OTRs
with melanomas of greater than 2 mm thickness
(American Joint Committee on Cancer [AJCC]
TNM stage T3 or T4) had a significantly worse
prognosis than did immunocompetent patients with
similar tumors, whereas the prognosis did not differ
in tumors of # 2 mm thickness (TNM stage T1 and
T2). These data indicate that iatrogenic immunosup-
pression may be associated with worse prognosis in
patients with thicker tumors and highlight the need
for close surveillance and early diagnosis in the OTR.
The initial approach to posttransplant primary
melanoma follows the same principles as the non-
transplanted general population. Surgical excision
with wide margins is the first step after diagnostic
biopsy and can cure tumors that have not spread. The
size of the surgical margin is guided by the Breslow
thickness of the primary lesion. Tumors of more than
4.0 mm require 2-cm margins, and, because of the
high risk of nodal and distant metastasis, in this
clinical setting more extensive surgical resection is
unlikely to yield better outcomes. The AJCC pub-
lished an international melanoma staging system that
guides melanoma prognosis and treatment in immu-
nocompetent patients.7 The AJCC predicted that 5-
year survival for patients with early, regional nodal,
and metastatic melanoma disease is 85%, 24% to
69.5%, and 6%, respectively, where the 24% to 69.5%
range varies according to the number of positive
lymph nodes at diagnosis.7 Sentinel lymph node
biopsy is indicated for tumors greater than 1-mm
Breslow thickness or in the presence of increased
mitotic activity and ulceration on histology. Sentinel
lymph node positivity is found to be the strongest
predictor of mortality in melanoma,4,8 and in nodal
disease, PET/CT or direct CT yield information about
tumor staging and disease progression. Surgicalcontrol was deemed unlikely in our patient, as she
presented with a primary lesion of 17.5-mm Breslow
thickness and positive lymph node status.
Completion lymphadenectomy was not performed
at diagnosis, as this procedure is not found to increase
survival in early nodal disease.9
There is no cure for metastatic melanoma, which
has a median survival time of 7.5 months from
diagnosis.10 Conventional treatment strategies, such
as surgery, chemotherapy, and radiotherapy are not
effective in limiting the progression of tumor metas-
tasis and are often associatedwith adverse effects and
poor quality of life. Reassuringly, immunotherapy
andmolecular targeted therapy have achieved partial
success in a subset of patients with unresectable
metastatic melanoma. High-dose interleukin-211
and, more recently, antieCTLA-4 (ipilimumab)12
and antiePD-1 (nivolumab)13 used as single agents
or in combination therapy, have achieved a long-term
survival of 5 years or longer. Dabrafenib and trame-
tinib, targeted BRAF and MEK1 inhibitors, respec-
tively, have achieved aprogression-free survival of up
to 3 years when used as monotherapy,14,15 although
as with most treatments based on oncogene-targeted
small molecules, tumor resistance has limited the
therapeutic response to these agents. Preclinical and
early development studies of combination dabrafe-
nib/trametinib have shown promising results, with
fewer side effects and less tumor resistance that either
agent used alone.16 Our patient had BRAF V600
mutant metastatic melanoma and was therefore
deemed a good candidate for enrollment in a phase
3 clinical trial testing combined BRAF and MEK
inhibitor treatment. She had an excellent initial
response to therapy, with progression-free survival
of 15 months or 5.5 months higher than the median
(9.4 months vs 6 to 7 months for monotherapy).16,17
Although these numbers are promising, at this
stage we cannot generalize her response to the
transplanted population as a whole. Further
research on melanoma outcomes in OTRs is
likely to inform effective treatment strategies in
relation to both immune therapy and reduction of
immunosuppression.
Melanoma is a potentially fatal complication of
transplantation, and severe disease can dramatically
reduce both the quality of life and the chance of
survival in OTRs. The optimal setting for treating
OTRs who have melanoma is a multidisciplinary
clinic led by the primary transplant team. In the
presence of life-threatening tumors, a reduction or
modification of immunosuppression should be
considered, after carefully balancing the risk of
allograft rejection against the risk of melanoma
mortality. Dermatologists play a key role in this
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able to quantify the tumor burden. A decision was
made against a reduction of immunosuppression in
our patient, as her cyclosporine regime was deemed
necessary to preserve allograft function.
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